Once withdrawn, the FDA no longer has an active safety-concern nomination to evaluate, so the substances come off the list by default
Dosing more frequently does not amplify effects proportionally and may lead to copper accumulation if total weekly copper delivery exceeds physiological handling capacity (approximately 1015mg elemental copper per week from all sources)
Additionally, patients with inflammatory bowel disease, severe gastroesophageal reflux disease, or other significant gastrointestinal disorders should be monitored closely if treatment is initiated, as the gastrointestinal effects of semaglutide may worsen their underlying condition
The gut mucosal response appears consistent across sex and hormonal status, making gut lining indications a strong match for female patients who are dealing with the GI consequences of hormonal fluctuation, antibiotic cycles, or inflammatory conditions
Both are on the July 2026 Pharmacy Compounding Advisory Committee agenda for 503A compounding review, which is a separate regulatory question from approval
